宫颈癌近距离放射治疗疼痛管理的研究进展

doi:10.13481/j.1671-587x.20190140

[1] KARLSSON J,DREIFALDT A C,MORDHORST L B, et al. Differences in outcome for cervical cancer patients treated with or without brachytherapy[J]. Brachytherapy, 2017, 16(1):133-140.
[2] WANG W,HOU X,YAN J, et al. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women[J]. BMC Cancer, 2017, 17(1):510.
[3] KWEKKEBOOM K L,DENDAAS N R,STRAUB M, et al. Patterns of pain and distress during high-dose-rate intracavity brachytherapy for cervical cancer[J]. J Support Oncol, 2009, 7(3):108-114.
[4] WARNOCK C. Patients' experiences of intracavity brachytherapy treatment for gynaecological cancer[J]. Eur J Oncol Nurs, 2005, 9(1):44-55.
[5] ROLLISON B,STRANG P. Pain, nausea and anxiety during intra-uterine brachytherapy of cervical carcinomas[J]. Support Care Cancer, 1995, 3(3):205-207.
[6] WIEBE E,SURRY K,DERRAH L, et al. Pain and symptom assessment during multiple fractions of gynecologic high-dose-rate brachytherapy[J]. Brachytherapy, 2011,10(5):352-356.
[7] BHANABHAI H,SAMANT R,E C, et al. Pain assessment during conscious sedation for cervical cancer high-dose-rate brachytherapy[J]. Curr Oncol, 2013, 20(4):e307-310.
[8] CORN B W,HANLON A L,PAJAK T F, et al. Technically accurate intracavitary insertions improve pelvic control and survival among patients with locally advanced carcinoma of the uterine cervix[J]. Gynecol Oncol, 1994, 53(3):294-300.
[9] WATANABE NEMOTO M,NOZAKI-TAGUCHI N,TOGASAKI G, et al. New approach to relieving pain and distress during high-dose-rate intracavitary irradiation for cervical cancer[J]. Brachytherapy, 2015, 14(5):642-647.
[10] BANSAL R,KHAN JOAD A S,SAXENA M, et al. Oral midazolam is a safe and effective premedication in adult outpatients undergoing brachytherapy for cancer cervix under general anaesthesia:A prospective randomised, double blind placebo-controlled study[J]. Indian J Anaesth, 2015,59(7):437-439.
[11] KAMER S,OZSARAN Z,CELIK O, et al. Evaluation of anxiety levels during intracavitary brachytherapy applications in women with gynecological malignancies[J]. Eur J Gynaecol Oncol, 2007, 28(2):121-124.
[12] HILLER J G,ISMAIL H M,HOFMAN M S, et al. Neuraxial anesthesia reduces lymphatic flow:proof-of-concept in first in-human study[J]. Anesth Analg, 2016, 123(5):1325-1327.
[13] SMITH M D, TODD J G,SYMONDS R P. Analgesia for pelvic brachytherapy[J]. Br J Anaesth, 2002, 88(2):270-276.
[14] VISWANATHAN A N,CREUTZBERG C L,CRAIGHEAD P, et al. International brachytherapy practice patterns:a survey of the Gynecologic Cancer Intergroup (GCIG)[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1):250-255.
[15] JONES B,TAN L T,BLAKE P R, et al. Results of a questionnaire regarding the practice of radiotherapy for carcinoma of the cervix in the UK[J]. Br J Radiol, 1994, 67(804):1226-1230.
[16] PETRIC P,HUDEJ R,HANUNA O, et al. MRI-assisted cervix cancer brachytherapy pre-planning, based on application in paracervical anaesthesia:final report[J]. Radiol Oncol, 2014, 48(3):293-300.
[17] PROUD C. The use of oral transmucosal fentanyl citrate during high-dose-rate gynecologic brachytherapy[J]. Clin J Oncol Nurs, 2007, 11(4):561-567.
[18] XU-WELLIVER M,LIN L L. Evaluation of a balloon-based vaginal packing system and patient-controlled analgesia for patients with cervical cancer undergoing high-dose-rate intracavitary brachytherapy[J]. Pract Radiat Oncol, 2013, 3(4):263-268.
[19] LEONG Y H,TAN K H S,AI CHOO B, et al. Novel anesthetic technique for combined intracavitary and interstitial brachytherapy for cervix cancer in an outpatient setting[J]. J Contemp Brachytherapy, 2017, 9(3):236-241.
[20] TAN P W, KOH V Y, TANG J L. Outpatient combined intracavitary and interstitial cervical brachytherapy:barriers and solutions to implementation of a successful programme-a single institutional experience[J]. J Contemp Brachytherapy, 2015, 7(3):259-263.
[21] TANGSIRIWATTHANA T,SANGKOMKAMHANG U S,LUMBIGANON P, et al. Paracervical local anaesthesia for cervical dilatation and uterine intervention[J]. Cochrane Database Syst Rev, 2009(1):CD005056.
[22] ANBUMANI S,ANCHINEYAN P,NARAYANASAMY A, et al. Treatment planning methods in high dose rate interstitial brachytherapy of carcinoma cervix:a dosimetric and radiobiological analysis[J]. ISRN Oncol, 2014, 2014:125020.
[23] TSUJINO K. The impact of general anesthesia usage during hdr intracavitary brachytherapy for cervical cancer on the quality of applicationsujino 2011[J]. Hyogo Cancer Center, 2011(2):S453-S454.
[24] LIM K H,LU J J,WYNNE C J, et al. A study of complications arising from different methods of anesthesia used in high-dose-rate brachytherapy for cervical cancer[J]. Am J Clin Oncol, 2004, 27(5):449-451.
[25] SHARMA D N,CHAUDHARI P,SHARMA S, et al. Comparison of high-dose-rate intracavitary brachytherapy dosimetry with and without anesthesia in patients with cervical carcinoma[J]. J Appl Clin Med Phys, 2014, 15(2):4670.
[26] JANAKI M G,NIRMALA S,KADAM A R, et al. Epidural analgesia during brachytherapy for cervical cancer patients[J]. J Cancer Res Ther, 2008, 4(2):60-63.
[27] VISWANATHAN A N,THOMADSEN B. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I:general principles[J]. Brachytherapy, 2012, 11(1):33-46.
[28] ROESSLER B,SIX L M,GUSTORFF B. Anaesthesia for brachytherapy[J]. Curr Opin Anaesthesiol, 2008, 21(4):514-518.
[29] BENRATH J,KOZEK-LANGENECKER S,HVPFL M, et al. Anaesthesia for brachytherapy-51/2 yr of experience in 1622 procedures[J]. Br J Anaesth, 2006, 96(2):195-200.
[30] WOJCIESZEK E,REMBIELAK A,BIALAS B, et al. Anaesthesia for radiation therapy-Gliwice experience[J]. Neoplasma, 2010, 57(2):155-160.
[31] WEITMANN H D,GUSTORFF B,VAUPEL P, et al. Oxygenation status of cervical carcinomas before and during spinal anesthesia for application of brachytherapy[J]. Strahlenther Onkol, 2003, 179(9):633-640.
[32] KIRCHHEINER K,CZAJKA-PEPL A,PONOCNY-SELIGER E, et al. Posttraumatic stress disorder after high-dose-rate brachytherapy for cervical cancer with 2 fractions in 1 application under spinal/epidural anesthesia:incidence and risk factors[J]. Int J Radiat Oncol Biol Phys, 2014, 89(2):260-267.
[33] JAIN R,MISHRA S, BHATNAGARS. Comparison of different anaesthetic techniques for high-dose-rate intracavitory radiotherapy for carcinoma cervix[J]. Int J Anesthesiol, 2008,17(1):8.
[34] MICHALEK-SAUBERER A, KOZEK-LANGENECKER S A,HEINZL H, et al. Median effective local anesthetic doses of plain bupivacaine and ropivacaine for spinal anesthesia administered via a spinal catheter for brachytherapy of the lower abdomen[J]. Reg Anesth Pain Med, 2008, 33(1):4-9.
[35] AMSBAUGH A K,AMSBAUGH M J,EL-GHAMRYM N, et al. Optimal epidural analgesia for patients diagnosed as having gynecologic cancer undergoing interstitial brachytherapy[J]. J Clin Anesth, 2016, 35:509-515.
[36] NIELSEN A A,LIYANAGE T A,LEISEROWITZ G S, et al. Optimal perioperative anesthesia management for gynecologic interstitial brachytherapy[J]. J Contemp Brachytherapy, 2017, 9(3):216-223.
[37] DAWKINS C J. An analysis of the complications of extradural and caudal block[J]. Anaesthesia, 1969, 24(4):554-563.
[38] NAG S, ERICKSON B,THOMADSEN B, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix[J]. Int J Radiat Oncol Biol Phys, 2000, 48(1):201-211.
[39] CHEN H C, LEUNG S W,WANG C J, et al. Local vaginal anesthesia during high-dose-rate intracavitary brachytherapy for cervical cancer[J]. Int J Radiat Oncol Biol Phys, 1998, 42(3):541-544.
[40] COUTAUX A,SALOMON L,ROSENHEIM M, et al. Care related pain in hospitalized patients:a cross-sectional study[J]. Eur J Pain, 2008, 12(1):3-8.
[41] MENDEZ L C,CHOI S,D'ALIMONTE L, et al. Opioid consumption and pain in gynecological cancer patients treated with interstitial brachytherapy[J]. Brachytherapy, 2017, 16(4):870-876.

Research progress in pain management of cervical cancer during brachytherapy

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 10

[1]	Hong LI,Panpan YU,Zouyu ZHAO,Chongfeng SUN,Hui QIAO,Ping YANG. Expression of GSTO1 in ovarian cancer tissue and effect of N-glycosylation site mutations on biological behaviors of epithelial ovarian cancer cells [J]. Journal of Jilin University(Medicine Edition), 2026, 52(2): 469-482.
[2]	Teng LIU,Ning ZHANG,Mingyuan HE,Guanghui CHENG. Research progress in treatment principles for endometrial cancer and its postoperative and postoperative recurrent radiotherapy [J]. Journal of Jilin University(Medicine Edition), 2025, 51(6): 1747-1754.
[3]	Ming CHEN,Qinghua LUO,Hongguang JIN,Liang HAN. Atypical lipomatous tumor of left lower limb: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1384-1389.
[4]	Rongmian YAN,Xinting SUN,Xin GUAN,Yu CHENG,Liying HAN. Effects of KLK5 overexpression on growth of subcutaneous xenograft tumor and cisplatin sensitivity in nude mice [J]. Journal of Jilin University(Medicine Edition), 2025, 51(5): 1194-1203.
[5]	Xialing HUANG,Dandan ZHANG,Xuemei ZHANG. Analysis on relationship between methylation of MSX1 gene and clinical pathological features and prognosis of patients with cervical cancer [J]. Journal of Jilin University(Medicine Edition), 2025, 51(3): 749-756.
[6]	Yanyan LU,Xiangbo XU,Yamei WU,Yuqi LIU,Han WANG,Lijuan YANG,Zhenjiang WANG,Zishen XIAO,Yanbo LIU. Eosinophil infiltration in cervical lesion and cervical cancer tissues and their clinical significances [J]. Journal of Jilin University(Medicine Edition), 2024, 50(6): 1691-1702.
[7]	Chunjing LIU,Yujie YANG,Wei ZHAO,Lijing LIU,Na WANG. Effect of silencing CDC20 on proliferation and cell cycle of endometrial cancer cells by inhibiting Wnt/β-catenin signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2024, 50(5): 1305-1312.
[8]	Changji ZHU,Xingzhe LIU,Yanhua XUAN. Effect of hypoxia on expressions of Gli1 and Sox2 in cervical cancer SiHa cells [J]. Journal of Jilin University(Medicine Edition), 2024, 50(2): 442-450.
[9]	Rongxia JIA,Xu ZHOU,Zhikun SHI,Meijing BAO,Guanqun WANG,Yuqing CHU,Yang LIN. Analysis on risk factors for disease progression of patients with cervical intraepithelial neoplasia Ⅰ [J]. Journal of Jilin University(Medicine Edition), 2022, 48(6): 1528-1534.
[10]	Guowu WANG,Yuan YAO,Yu ZHANG,Na XU,Fang LIU. Inhibitory effect of miR-152 on proliferation and invasion of endometrial carcinoma cells by reducing low-density lipoprotein receptor expression [J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 591-599.
[11]	Xingyu ZHAO,Xin YANG,Zhihua ZHU,Han HE,Zitong SONG,Wei ZHANG. Inhibitory effect of juglone on proliferation of cervical cancer cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2022, 48(2): 348-355.
[12]	Aiping WEN,Le LUO,Zhiwei MENG,Jingji JIN,Honggui ZHOU,Jihong ZHU. Expression of Tip60 protein in endometrial adenocarcinoma tissue and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2021, 47(5): 1244-1249.
[13]	Dongli ZHANG,Ruifang FU,Guixia SUN. Effect of oxymatrine on proliferation and apoptosis of cervical cancer SiHa cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2021, 47(4): 951-957.
[14]	Lijing QIN,Bing HAN,Zhongqi LI,Qi SUO,Zhen JIA,Hongli CUI,Weiqiang XU,Fang FANG,Zhicheng WANG. Effects of targeting-silenced ATRX on cell cycle arrest and apoptosis induced by radiation in cervical cancer HeLa cells [J]. Journal of Jilin University(Medicine Edition), 2021, 47(4): 904-910.
[15]	Dan SU, Yi LIU, Manman CUI, Nian YANG, Yu HUANG, Wenjing HE. Evaluation of clinical effect of screening chemotherapy regimens in treatment of ovarian cancer based on miniPDX animal models [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 731-739.